This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (August 2018) (Learn how and when to remove this template message)
Koronis Pharmaceuticals is a Seattle area biotechnology company founded in 1998. Koronis is dedicated to the development of antiviral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company’s lead product candidate is KP-1461 for the treatment of human immunodeficiency virus (HIV) infection. The company also has products in development for the treatment of hepatitis C and RSV infection.
- Hirschler, Ben, U.S. HIV drug firm Koronis looks to London listing, Reuters
- Cook, John (June 28, 2007), "Koronis' HIV drug draws funding; $20 million to be used for studies", Seattle P-I
- Dolan, Kerry A. (July 20, 2011), "Embracing The Enemy", Forbes
- Cook, John (August 2, 2005), "Biotech pioneer Gillis ventures into a new field", Seattle P-I
- Paulson, Tom. "Conflicts Advance a Burgeoning Field Industry, Academia Now are Bedfellows." Seattle P-I. May 19, 1999: A1.
- Biotech Industry Driven By Evolution Searching For Cures, Companies Get Creative. Carol Smith P-I Reporter. Seattle P-I. May 17, 1999: A1.
- Mature companies beat out new ones for VC cash. Romano, Benjamin J. Seattle Times. October 25, 2005: C1.
- Specter, Michael (December 3, 2007), "Darwin's Surprise", The New Yorker, vol. 83 no. 38, pp. 64-
- Mone, Gregory (February 2009), "The new virus killer: scientists try to turn HIV's greatest strength--mutation--against itself.", Popular Science, vol. 274 no. 2, pp. 27–
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|